Nicholas Denton
Overview
Explore the profile of Nicholas Denton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kiles T, Rosario N, Leslie K, Leslie K, Denton N, Dang D, et al.
Am J Pharm Educ
. 2025 Mar;
:101384.
PMID: 40032146
There is emerging scholarship related to teaching social determinants of health (SDOH) in pharmacy education; however, challenges remain as there is no formal consensus on which aspects of SDOH to...
2.
Fabijanczuk K, Yu Z, Bakestani R, Murtada R, Denton N, Gaspar K, et al.
Anal Chem
. 2023 Jan;
95(5):2932-2941.
PMID: 36715667
Inspired by the electron-activated dissociation technique, the most potent tool for glycan characterization, we recently developed free radical reagents for glycan structural elucidation. However, the underlying mechanisms of free radical-induced...
3.
Wojton J, Meisen W, Jacob N, Thorne A, Hardcastle J, Denton N, et al.
Oncotarget
. 2014 Sep;
5(20):9703-9.
PMID: 25210852
SapC-DOPS is a novel nanotherapeutic that has been shown to target and induce cell death in a variety of cancers, including glioblastoma (GBM). GBM is a primary brain tumor known...
4.
Wojton J, Chu Z, Mathsyaraja H, Meisen W, Denton N, Kwon C, et al.
Mol Ther
. 2013 Jun;
21(8):1517-25.
PMID: 23732993
Saposin C-dioleoylphosphatidylserine (SapC-DOPS) nanovesicles are a nanotherapeutic which effectively target and destroy cancer cells. Here, we explore the systemic use of SapC-DOPS in several models of brain cancer, including glioblastoma...